Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Herantis Pharma announces first healthy volunteer dosed in the Phase 1a clinical study for the Parkinson’s disease drug candidate, HER-096

Herantis Pharma Plc, Press release, 19 April 2023 at 11 a.m. EEST The Phase 1a clinical study will assess safety, tolerability, and blood-brain barrier penetration of subcutaneously administered HER-096. Herantis Pharma Plc ("Herantis"), a company developing disease-modifying therapies for Parkinson’s disease, is pleased to announce the dosing of the first healthy volunteer in the Phase 1a clinical study for HER-096. “We are excited to start the Phase 1a clinical study with HER-096. This is an important milestone on our way towards developing a disease-modifying therapy for slowing

Save the date: Storytel Capital Markets Day on June 13, 2023

Today, Storytel announced that the company will hold a Capital Markets Day on June 13, 2023. The Storytel Capital Markets Day will provide an opportunity for institutional investors, financial analysts and financial media to get an update on Storytel’s position and operations as well as its strategy and financial targets going forward. The event will commence at 2 PM CEST and the agenda will include presentations by CEO Johannes Larcher and members of the executive management.The Storytel Capital Markets Day will be held at a venue in downtown Stockholm, Sweden, where the headquarters of

Valmet to deliver an automation system to Sibanye-Stillwater’s Keliber lithium refinery in Kokkola, Finland

Valmet Oyj’s trade press release on April 19, 2023 at 11:00 a.m. EESTValmet will deliver a Valmet DNA automation system  to a lithium project run by Sibanye-Stillwater’s subsidiary Keliber in Kokkola, Finland. The order is included in Valmet’s orders received of the first quarter 2023. The construction of the lithium refinery has started in March 2023. “Battery chemicals are an interesting process area and there is a lot of future potential. Automation plays an important role in process reliability, usability and

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 99 - 19 APRIL 2023 In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 40/23 and 42/23.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Thomas France, Investor Communications Partner, tel.: 3315 0451

BioStock: FDA grants Abliva’s NV354 Orphan Drug Designation

Biotech Abliva kicked the week off by announcing positive news from the United States. The FDA grants Abliva’s candidate NV354 Orphan Drug Designation, a designation that entails several regulatory advantages for the candidate. BioStock talked to CEO Ellen K. Donnelly about what this means for the development of NV354.Read the interview with Abliva's CEO Ellen K. Donnelly at biostock.se: https://www.biostock.se/en/2023/04/fda-grants-ablivas-nv354-orphan-drug-designation/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

The subscription period in BoMill’s rights issue begins today

Today, April 19, 2023, the subscription period commences in BoMill AB’s (“BoMill” or the “Company”) rights issue of a maximum of 46 529 070 shares with a subscription price of SEK 0.47 per share (the “Rights Issue") resolved by the Extraordinary General Meeting of BoMill on April 6, 2023.The Company may receive up to SEK 21.9 million from the Rights Issue before issue costs. The subscription period runs from today and up until and including May 3, 2023. The proceeds from the Rights Issue are primarily intended to finance sales and marketing activities in scaling up the commercialization of

Minesto participating in Stockholm Climate Week today

As a part of Stockholm Climate Week that leads up to Earth Day 2023, Minesto CEO Dr Martin Edlund will be taking part in a panel discussion at SPACE Arena in Stockholm today.The panel discussion around the topic ‘Reimagining Energy Solutions’ will take place at 16.45 – 17.30 CEST today on 19 April. By scaling up new solutions that produce renewable energy, reduce energy consumption, and reimagine how energy is used, we can achieve significant emissions reductions. The panel will be streamed live online. Read more and watch the livestream here: Stockholm Climate Week – Energy &

Eficode receives Atlassian Partner of the Year 2022: Services EMEA

Helsinki, April 19, 2023 - Atlassian announced today that Eficode has received Atlassian Partner of the Year 2022 Services EMEA for its outstanding contribution and achievements during the calendar year 2022. This includes exceptional efforts in developing new business, thought leadership, and products and services  that complement Atlassian. Eficode was one of 26 global partner recipients honored in the annual Atlassian Partner of the Year program for its continuous efforts and exceptional customer work. "Year over year, I am surprised and delighted by

Read original

SSC invests to become an industry leader in sustainable space activities

SSC is increasing its contribution to a sustainable social development through a number of initiatives. Among the initiatives is the newly inaugurated Spaceport Esrange where satellites will be launched from 2024, as well as a new membership in the global Exponential Roadmap Initiative with the aim of making SSC sustainable throughout the company’s entire value chain. In SSC's latest Annual and Sustainability report , a selection of the investments are presented. “We have a proud heritage as one of the industry’s leading

Nordic Capital acquires majority share in corpuls to support further development of the high-growth med-tech company

· corpuls is a leading global medical technology provider, focusing on high quality and innovative products for professional users in emergency situations. · The Company sells its products in more than 60 countries with a particular focus on portable defibrillator and monitoring systems as well as devices for mechanical chest compression and the corresponding software solutions.  · Based on its extensive experience in the healthcare sector, Nordic Capital will support corpuls’ continued growth trajectory in close partnership with the founding family and the management team, while

Salmon Evolution ASA: Notice of Extraordinary General Meeting

19 April 2023: Reference is made to the stock exchange announcements by Salmon Evolution ASA (“Salmon Evolution” or the “Company”) on 19 April 2023 regarding a successfully placed private placement (the “Private Placement”) of new shares in the Company, and a potential subsequent offering (the “Subsequent Offering”). Salmon Evolution hereby calls for an extraordinary general meeting (“EGM”) in the Company to be held on 11 May 2023 at 11:00 (Oslo time), where the approval of share capital increase pertaining to tranche 2 of the Private Placement and a board authorization to issue new

Avensia Partners With Bluestone PIM

Modern commerce expert Avensia has entered a strategic partnership with Bluestone PIM , a rapidly growing product information management solution with global presence. The new agreement allows Avensia to meet specific customer demands and expand reach to new target audiences.Information management is one of Avensia’s core competence areas. The Avensia team has thorough knowledge and extensive experience in supporting businesses with strategies, processes and technology for efficient information management. Current technology partners include global leaders

Invitation to presentation of Bravida’s report for the first quarter 2023

Bravida’s report for the first quarter 2023 will be published 07:30 CET on 3 May 2023.The report will be presented at 09:30 CET by CEO and Group President Mattias Johansson and CFO Åsa Neving. The presentation will be held in English and can be followed on the web or on the phone. There will be room for questions in the telephone conference. Link to webcasthttps://ir.financialhearings.com/bravida-holding-q1-2023/register Telephone conference dial-in numberSE:  +46-8-5051-6386UK:  +44-20-319-84884US:  +1-412-317-6300PIN:  5403368# The report and presentation will be

Towards harvest 2023 – spring farming in full swing

Somewhat later than usual, Swedish farmers are now starting the intensive work with spring farming. Large autumn sowing, a mild winter rest and stable global demand are factors that will affect the harvest year 2023. The conditions are good for a normal-sized Swedish harvest, but as always, the harvest outcome is ultimately determined by the weather.After large autumn sowing, a mild winter rest and a spring with more precipitation than usual, spring farming is now beginning in large parts of southern and central Sweden. The autumn crops, with the exception of the autumn-sown rapeseed, have

Read original

Major Shareholding Disclosure – Private Placement

19 April 2023: Reference is made to the stock exchange notice by Salmon Evolution ASA (the “Company”) on 19 April 2023 regarding the successfully placed private placement of a total of 68,181,818 new shares in the Company with a subscription price of NOK 7.7 per share divided into two tranches, whereby tranche 1 consisting of 51,863,220 shares and tranche 2 consisting of 16,318,598 shares (the “Private Placement”). Farvatn Private Equity AS was allocated 1,290,000 shares in the Private Placement. Upon completion of the Private Placement through the issue of all shares in the Private

BioStock: Chordate presents study results for the American Headache Society

The final results from Chordate Medical’s PM007 study show that K.O.S. has a significant effect for the preventive treatment of chronic migraine. The results will be presented at the American Headache Society Scientific Meeting in mid-June and are also available on the organisation’s website.Read the full article at biostock.se: https://www.biostock.se/en/2023/04/chordate-presents-study-results-for-the-american-headache-society/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Clinical Laserthermia Systems Announces Agreement with AVANT Concierge Urology to Treat Prostate Cancer Patients with TRANBERG Thermal Therapy System

Lund, Sweden – April 19, 2023 – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) today announces that their US subsidiary CLS Americas has signed a Mobile Service Provider (MSP) Agreement with AVANT Concierge Urology  of Winterhaven, FL.Under the agreement, AVANT will begin using the CLS TRANBERG Thermal Therapy System  to treat patients with early-intermediate stage prostate cancer. According to the agreement, CLS provides its 510(k) cleared TRANBERG Thermal Therapy System, with consumable accessories,

Fazer includes food loss as a metric in its 2023 Short-Term Incentive plan

Fazer’s Board of Directors has decided to broaden the ESG (Environmental, Social, and Governance) criteria in the company’s Short-Term Incentive plan (STI), and to include food loss as a metric, in addition to Employee Safety, which has long been an ESG priority for Fazer. The portion of the ESG basket in the 2023 STI plan amounts to 15% of the total, highlighting the importance of ESG to the Group. The remainder of the annual STI performance criteria include Group and Business Area financial performance related goals.Food loss has a major impact on climate, water, land and biodiversity.

Observit AB publishes stock analysis from Carlsquare and summons to an extraordinary General meeting ahead of listing.

Carlsquare has published a stock analysis regarding Observit AB, which was distributed to SpectrumOne’s shareholders during July 2022. SpectrumOne still holds 16,7 % of the shares in Observit AB. In the analysis, Carlsquare points to a share price between SEK 0.28 – 0.48/share in a base and a bull scenario respectively. Furthermore, Observit AB has summoned to an extraordinary General meeting to elect Thomas Jönsson and Johan Lembre as new board members. Johan Lembre is CTO at the lighting company Fagerhult Group and before that Johan was CEO at the Swedish headphone company Earin. He

Katalysen portfolio company InvitePeople reports strong progress in German market

Katalysen Ventures is excited to announce that portfolio company and event-tech leader InvitePeople has entered the DACH region, with the aim to replicate its Nordic-market success in the ten times larger German-speaking European market.InvitePeople, the virtual platform for true digital and hybrid events and meetings, has formally entered the large German-speaking European market by acquiring a Berlin-based company with about 10 employees. This Berlin-based company has now been transformed from its previous event-related business to become the foundation for InvitePeople Germany, selling

NOTE’s Interim Report January–March 2023

Financial performance January–March• Sales increased by 28% to SEK 1,051 (821) million. Adjusted for acquisitions and currency effects, organic growth was 14%.• Operating profit increased by 48% to SEK 112 (76) million.• The operating margin widened by 1.4 percentage points to 10.7% (9.3%).• Profit after financial items was up by 50% to SEK 104 (69) million.• Profit after tax rose by 51% to SEK 85 (56) million, corresponding to SEK 2.92 (1.95) per share.• Cash flow after investments amounted to SEK 49 (9) million, or SEK 1.69 (0.31) per share. Adjusted for acquisition-related

Invitation to presentation of BioArctic’s first quarter report for January - March 2023 on April 27 at 9.30 a.m. CET

Stockholm, Sweden, April 19, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s first quarter report for January – March 2023 on Thursday, April 27, 2023, at 08:00 a.m. CET.In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on April 27, at 09:30 CET, where Gunilla Osswald, CEO, and Jan Mattsson, CFO, will present BioArctic and comment on the first quarter report for January – March 2023, followed by a Q&A-session. If you wish to participate via webcast, please use the link below.

Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)

N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the annual general meeting. In case of any discrepancies between the Swedish and English language versions, the Swedish version shall prevail. April 19 2023 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820 (the “Company”), are hereby summoned to the Annual General Meeting on Wednesday May 24, 2023 at 17.00 (CET) at Setterwalls Advokatbyrå’s offices at Sturegatan 10 in Stockholm. Registration for the meeting commences at 16.30 (CET).NoticeShareholders wishing to

There are no items matching the current filter
There are no more items matching the current filter
Back to top